Taro Q4 net income spikes 70% to $152.3 mn

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Taro Pharmaceutical Industries's fourth quarter net income grew by 70 percent to USD 152.3 million compared to USD 89.6 million in the year-ago period. Higher revenue, operational performance and forex income helped the bottomline.

Net sales increased 30.5 percent to USD 244.2 million.

The Israel-based pharma company and the subsidiary of Sun Pharmaceutical has reported forex income of USD 32.5 million during the quarter against USD 3.9 million in the same quarter last year due to favourable currency fluctuation.

During the quarter, it filed 5 abbreviated new drug applications with the US Food and Drug Administration. Its research and development costs (as a percentage of sales) increased by 430 basis points sequentially.

Operating income climbed 51.2 percent year-on-year to USD 153.5 million and margin expanded by 860 basis points to 62.9 percent in the quarter gone by.

Credit Suisse has maintained its outperform rating on the stock. Company recently pushed through price increases of a two derma products and both the drugs together could add incremental sales of USD 30-35 million, said the brokerage. Both drugs can boost current sales run rate of Taro by 4 percent and EBITDA by 5 percent, it added.